Complete Genomics, Inc. (NASDAQ:GNOM) has traded as high as $4.18 during today’s trading session and last traded at the high of the day for a gain of 27.05% from Friday’s close… GNOM shares have traded as high as $18.55 over the last 52 weeks, which is 77.46% off that high at last traded stock price.
Complete Genomics announced today that it has been selected by Mayo Clinic’s Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics’ sequencing service for some of its large-scale whole genome sequencing projects. Get my next ALERT 100% FREE
The Center for Individualized Medicine operates a comprehensive sequencing laboratory in its own Medical Genome Facility, but it determined that collaboration with Complete Genomics could supplement the services available to its community of medical researchers. Under the terms of the agreement, Mayo Clinic can send genetic material to Complete Genomics for sequencing and analysis. It will continue to operate and invest in its Medical Genome Facility. Financial details of the agreement were not disclosed.
“Mayo Clinic, through the Center for Individualized Medicine, already has several high-impact genome- and epigenome-based studies underway in individualized care for our patients,” said Gianrico Farrugia, M.D., director of Mayo Clinic’s Center for Individualized Medicine. “Access to quality whole genome sequencing services can only expedite our efforts to improve care for all of our patients with new individualized medicine tools and techniques.”
“It is exciting to see a world-renowned healthcare organization like Mayo Clinic take the next step towards bringing high-quality whole genome sequencing data into the clinic. They clearly recognize its potential to personalize treatment options and improve the future quality of patient care,” said Leroy Hood, M.D., Ph.D., president of the Institute for Systems Biology and a member of Complete Genomics’ Scientific Advisory Board. “This is a big step toward the realization of personalized medicine.”
“For well over a century, Mayo Clinic has been an innovator and leader in translating cutting-edge clinical research into world-class patient care and treatment,” said Clifford Reid, Ph.D., chairman, president and CEO of Complete Genomics. “We are honored to be partnering with Mayo Clinic researchers to provide sequencing and analysis for their genomic studies and investigations.”
Projects will be coordinated with the Center of Individualized Medicine’s Medical Genome Facility and will help expedite Mayo Clinic’s translational genomics-based programs. Through these initiatives, Mayo Clinic will develop best practices for using genetic information to guide patient care.
Mayo’s effort is part of a growing trend in medicine to collect and analyze the genetic information from consenting patients to optimize medical care in a variety of disciplines, including cancer diagnosis and treatment, drug therapy, disease prevention, and many others. This information could also be used by doctors to advise patients about lifestyle changes that could help prevent or delay disease onset.
About StockPreacher.com
StockPreacher.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
StockPreacher Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. StockPreacher.com is a wholly owned subsidiary of BlueWave Advisors. BlueWave Advisors has not been compensated, and holds no positions in any of the stocks mentioned in this article.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
